Avastin v. Lucentis Trial Hits Snag: Co-Pays Essentially Unblind NIH Study

In addition to roiling physicians and patients, the cost disparity between Lucentis (ranibizumab) and Avastin (bevacizumab) may also be undermining the study design of a head-to-head comparison of the two Genentech drugs, the lead investigator says